Evidence map›Paper›PMID 25502630›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015

'Second-generation' mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function.

Kusumika Saha, John S Partilla, Kurt R Lehner, Amir Seddik, Thomas Stockner, Marion Holy, Walter Sandtner, Gerhard F Ecker, Harald H Sitte, Michael H Baumann

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review.International journal of molecular sciences · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Structure-Activity Relationship ofACS chemical neuroscience · 2023
    Article
  12. Article
  13. Review
  14. Review
  15. An updated review on synthetic cathinones.Archives of toxicology · 2021
    Review
  16. Worsening of the Toxic Effects of (±)International journal of molecular sciences · 2021
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Kusumika SahaMedical University of Vienna, Center for Physiology and Pharmacology, Institute of Pharmacology, Vienna, Austria.
John S PartillaDesigner Drug Research Unit (DDRU), Intramural Research Program (IRP), NIDA, NIH, Baltimore, MD, USA.
Kurt R LehnerDesigner Drug Research Unit (DDRU), Intramural Research Program (IRP), NIDA, NIH, Baltimore, MD, USA.
Amir SeddikDepartment of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
Thomas StocknerMedical University of Vienna, Center for Physiology and Pharmacology, Institute of Pharmacology, Vienna, Austria.
Marion HolyMedical University of Vienna, Center for Physiology and Pharmacology, Institute of Pharmacology, Vienna, Austria.
Walter SandtnerMedical University of Vienna, Center for Physiology and Pharmacology, Institute of Pharmacology, Vienna, Austria.
Gerhard F EckerDepartment of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
Harald H Sitte1] Medical University of Vienna, Center for Physiology and Pharmacology, Institute of Pharmacology, Vienna, Austria [2] Medical University of Vienna, Center for Addiction Research and Science, Vienna, Austria.
Michael H BaumannDesigner Drug Research Unit (DDRU), Intramural Research Program (IRP), NIDA, NIH, Baltimore, MD, USA.
Medical University of Vienna · ATNational Institute on Drug Abuse · USUniversity of Vienna · AT

Funding

IMPROVING HEALTH CARE UTILIZATION IN HIV+ DRUG USERSK23DA000523 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GEBO, KELLY A · 2001 to 2005
$794k
Studies on MDMA and Related CompoundsZ01DA000523 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI ROTHMAN, RICHARD · 2008 to 2008
$199k
Austrian Science Fund FWF W 1232Intramural NIH HHS Z01 DA000523NIDA NIH HHS DA000523-07NIDA NIH HHS K23 DA000523
6 · The paper itself

Abstract

The nonmedical use of synthetic cathinones is increasing on a global scale. 4-Methyl-N-methylcathinone (mephedrone) is a popular synthetic cathinone that is now illegal in the United States and other countries. Since the legislative ban on mephedrone, a number of 'second-generation' analogs have appeared in the street drug marketplace, including 4-methyl-N-ethylcathinone (4-MEC) and 4'-methyl-α-pyrrolidinopropiophenone (4-MePPP). Here we characterized the interactions of 4-MEC and 4-MePPP with transporters for 5-HT (SERT) and dopamine (DAT) using molecular, cellular, and whole-animal methods. In vitro transporter assays revealed that 4-MEC displays unusual 'hybrid' activity as a SERT substrate (ie, 5-HT releaser) and DAT blocker, whereas 4-MePPP is a blocker at both transporters but more potent at DAT. In vivo microdialysis experiments in rat brain demonstrated that 4-MEC (1-3 mg/kg, i.v.) produced large increases in extracellular 5-HT, small increases in dopamine, and minimal motor stimulation. In contrast, 4-MePPP (1-3 mg/kg, i.v.) produced selective increases in dopamine and robust motor stimulation. Consistent with its activity as a SERT substrate, 4-MEC evoked inward current in SERT-expressing Xenopus oocytes, whereas 4-MePPP was inactive in this regard. To examine drug-transporter interactions at the molecular level, we modeled the fit of 4-MEC and 4-MePPP into the binding pockets for DAT and SERT. Subtle distinctions in ligand-transporter binding were found that account for the differential effects of 4-MEC and 4-MePPP at SERT. Collectively, our results provide key information about the pharmacology of newly emerging mephedrone analogs, and give clues to structural requirements that govern drug selectivity at DAT vs SERT.

Indexed as

AmphetaminesAnimalsBrainDopamineDopamine AgentsDopamine Plasma Membrane Transport ProteinsHEK293 CellsHumansMaleMolecular Docking SimulationMotor ActivityOocytesPropiophenonesPyrrolesRats, Sprague-DawleySerotonin4'-methyl-alpha-pyrrolidinopropiophenone4-methylethcathinoneAmphetaminesDopamineDopamine AgentsDopamine Plasma Membrane Transport ProteinsPropiophenonesPyrrolesSerotoninSerotonin AgentsSerotonin Plasma Membrane Transport Proteins

Identifiers

PMID25502630
PMCPMC4397398
OpenAlexW2024418623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.